Advancing The Use of Oral Anticoagulants in Atrial Fibrillation and Venous Thromboembolism

Well-being, Health and Biomedical Discovery


Academic Unit: inquire with unit

Memorial Deadline: Monday 29th, April 2024

External Deadline: Monday 6th, May 2024


Pfizer and Bristol-Myers Squibb (BMS) are collaborating to provide grant support for continuing professional education in the areas of atrial fibrillation and venous thromboembolism. We are committed to supporting innovative, independent medical education for healthcare professionals.

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer and BMS must not be involved in any aspect of project development, nor the conduct of the independent education program.

Date RFP Issued: March 28, 2024

Geographic Scope: Global (not including the US)

Clinical Area: Atrial Fibrillation/Venous Thromboembolism

Link to full RFP: Advancing the Use of Oral Anticoagulants in Atrial Fibrillation and Venous Thromboembolism

Application Due Date: May 06, 2024

Specific Area of Interest: Projects that will be considered for support will focus on improving the care of patients by addressing knowledge gaps in Atrial Fibrillation and stroke prevention or Venous Thromboembolism or both areas.

Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to Miguel Briceno (

Funding Sources

Bristol Myers Squibb
Pfizer Inc

This opportunity was posted by: RGCS

Last modified: March 28, 2024